Tyrosine kinase inhibitors significantly improved survival outcomes in patients with metastatic gastrointestinal stromal tumour: a multi-institutional cohort study.
gastrointestinal stromal tumour
gist
imatinib
real-world data
sarcoma
sunitinib
tyrosine kinase inhibitors
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
17
7
2020
pubmed:
17
7
2020
medline:
5
6
2021
Statut:
ppublish
Résumé
The real-world impact of tyrosine kinase inhibitors (tkis) in clinical practice for gastrointestinal stromal tumour (gist) has not been extensively reported. We sought to assess how outcomes have changed over the eras and to evaluate the effect of access to imatinib and sunitinib on survival in patients with unresectable or metastatic gist in British Columbia. Patients with metastatic or unresectable gist were allocated to one of three eras: pre-2002, 2002-2007, and post-2007 based on treatment availability (pre-imatinib, post-imatinib, and post-sunitinib). Overall survival (os) and progression-free survival (pfs) were compared between eras. Univariate and multivariate analyses were performed to determine the effects of tumour, patient, and treatment characteristics on survival outcomes. Of 657 patients diagnosed with gist throughout British Columbia during 1996-2016, 196 had metastatic disease: 23 in the pre-imatinib era, 67 in the post-imatinib era, and 106 in the post-sunitinib era. A significant increase in os, by 53.6 months ( Implementation of tkis has drastically improved survival outcomes for patients with metastatic gist by up to 4.55 years in the real-world setting. Our study demonstrates that implementation of tkis in clinical practice has outperformed their benefit predicted in clinical trials.
Sections du résumé
Background
The real-world impact of tyrosine kinase inhibitors (tkis) in clinical practice for gastrointestinal stromal tumour (gist) has not been extensively reported. We sought to assess how outcomes have changed over the eras and to evaluate the effect of access to imatinib and sunitinib on survival in patients with unresectable or metastatic gist in British Columbia.
Methods
Patients with metastatic or unresectable gist were allocated to one of three eras: pre-2002, 2002-2007, and post-2007 based on treatment availability (pre-imatinib, post-imatinib, and post-sunitinib). Overall survival (os) and progression-free survival (pfs) were compared between eras. Univariate and multivariate analyses were performed to determine the effects of tumour, patient, and treatment characteristics on survival outcomes.
Results
Of 657 patients diagnosed with gist throughout British Columbia during 1996-2016, 196 had metastatic disease: 23 in the pre-imatinib era, 67 in the post-imatinib era, and 106 in the post-sunitinib era. A significant increase in os, by 53.6 months (
Conclusions
Implementation of tkis has drastically improved survival outcomes for patients with metastatic gist by up to 4.55 years in the real-world setting. Our study demonstrates that implementation of tkis in clinical practice has outperformed their benefit predicted in clinical trials.
Identifiants
pubmed: 32669934
doi: 10.3747/co.27.5869
pii: conc-27-e276
pmc: PMC7339857
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e276-e282Informations de copyright
2020 Multimed Inc.
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare that we have none.
Références
J Clin Oncol. 2010 Mar 1;28(7):1247-53
pubmed: 20124181
Oncologist. 2007 Jan;12(1):107-13
pubmed: 17227905
World J Surg Oncol. 2009 Aug 01;7:61
pubmed: 19646278
Br J Clin Pharmacol. 2004 Jan;57(1):86-92
pubmed: 14678345
Clin Trials. 2006;3(6):508-12
pubmed: 17170034
Science. 2003 Jan 31;299(5607):708-10
pubmed: 12522257
Ther Adv Med Oncol. 2014 Sep;6(5):222-8
pubmed: 25342989
Cancer Epidemiol. 2016 Feb;40:39-46
pubmed: 26618334
Can J Gastroenterol. 2006 Mar;20(3):157-63
pubmed: 16550259
Int J Clin Exp Pathol. 2010 May 05;3(5):461-71
pubmed: 20606727
Am J Surg Pathol. 2004 Jul;28(7):889-94
pubmed: 15223958
Hum Pathol. 2002 May;33(5):466-77
pubmed: 12094371
Annu Rev Pathol. 2008;3:557-86
pubmed: 18039140
Science. 1998 Jan 23;279(5350):577-80
pubmed: 9438854
Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34
pubmed: 15451219
Oncologist. 2009 Feb;14(2):174-80
pubmed: 19193781
Lancet. 2006 Oct 14;368(9544):1329-38
pubmed: 17046465
Semin Diagn Pathol. 2006 May;23(2):70-83
pubmed: 17193820
J Clin Oncol. 2005 Aug 10;23(23):5357-64
pubmed: 15928335
Blood. 2000 Aug 1;96(3):925-32
pubmed: 10910906
J Cancer Res Clin Oncol. 2010 Jul;136(7):1065-71
pubmed: 20043176
Ther Adv Med Oncol. 2012 Sep;4(5):255-70
pubmed: 22942908
Rare Tumors. 2011 Oct 21;3(4):e35
pubmed: 22355490
Am J Surg Pathol. 1999 Jan;23(1):82-7
pubmed: 9888707
J Clin Oncol. 2008 Feb 1;26(4):626-32
pubmed: 18235122
Eur J Cancer. 2015 Nov;51(16):2423-33
pubmed: 26248685
J Gastrointest Oncol. 2012 Sep;3(3):189-208
pubmed: 22943011
Clin Cancer Res. 2012 Jun 1;18(11):3170-9
pubmed: 22661587
Am J Surg Pathol. 2005 Jan;29(1):52-68
pubmed: 15613856